Navigation Links
Re-awakening old genes to help in the fight against HIV
Date:4/27/2009

A new vaginal cream containing a reawakened protein could someday prevent the transmission of HIV.

Scientists at the University of Central Florida in Orlando have revived a dormant gene found in humans and coaxed it to produce retrocyclin, a protein that resists HIV.

Lead scientist Alexander Cole used aminoglycosides, drugs commonly used to fight bacterial infections, to trigger the production of the sleeping protein expressed by the retrocyclin gene.

"It could make a huge difference in the fight against HIV," Cole said. "Much more work would be needed to demonstrate the safety and effectiveness of this approach. We would certainly have to have human trials, but these findings represent a promising step in that direction."

Findings from his three-year investigation are published in this month's PLOS Biology, a well-respected scientific journal.

HIV is the virus that causes AIDS. The disease, most often transmitted sexually, affects 4.3 million people worldwide, according to the World Health Organization. About 14,560 people die annually from HIV-related complications each year in the United States alone, according to the Centers for Disease Control.

Dozens of scientists around the world are looking for ways to prevent the transmission of the disease. Cole's journey into this area of research began while he was a postdoctoral fellow in the Department of Medicine at the University of California at Los Angeles. While there, he and his colleagues discovered that similar retrocyclin proteins found in early primates appeared to prevent HIV infections in cell cultures. The same gene exists in humans, but because of a mutation, it no longer produces the protein.

Now, in collaboration with researchers at UCLA, the Centers for Disease Control and his team at UCF, Cole has found that restoring the production of retrocyclins prevents HIV entry. He found a way to get the gene to produce the retrocyclins and then showed that the retrocyclins appear to prevent the transmission of HIV. He applied aminoglycoside antibiotics to vaginal tissues and cervical cells in his lab and found the antibiotic appears to stimulate those cells and tissues to produce retrocyclins on their own.

He said there is a good possibility the aminoglycoside antibiotics will be used in a cream or gel format that could someday be a simple way to prevent the transmission of HIV from men to women.


'/>"/>

Contact: Zenaida Gonzalez Kotala
zkotala@mail.ucf.edu
407-823-6120
University of Central Florida
Source:Eurekalert  

Related biology news :

1. SUMO protein guides chromatin remodeler to suppress genes
2. Major international study challenges notions of how genes are controlled in mammals
3. Findings show insulin -- not genes -- linked to obesity
4. Genes from tiny marine algae suggest unsuspected avenues for new research
5. Genes from tiny algae shed light on big role managing carbon in worlds oceans
6. Genes that make bacteria make up their minds
7. Team IDs genesis of mass migrations
8. Hopkins scientists ID 10 genes associated with a risk factor for sudden cardiac death
9. Ten genes identified in connection with sudden cardiac death
10. Genes identified that are linked to spinal disc degeneration
11. Cleft lip and palate: Genes more important than thought?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Re-awakening old genes to help in the fight against HIV
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
Breaking Biology Technology: